$6715 | SAVE $1,185 | Single User
$17425 | SAVE $3,075 | Global License

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight
[Lowest Price Guaranteed: $6,715]

Published by FirstWord Pharma: 01 Sep 2016 | 65303 | In Stock
Related Topics: Gas , Gastroenterology , Hepatology , Medical , Roche

Introduction

Are UC biosimilars a real or perceived threat to branded drugs?

Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; first-mover, Entyvio has a direct competitor coming on stream; and there is even talk of combination therapies and natural treatments in some quarters. What are the most influential key opinion leaders (KOLs) saying about market dynamics for UC drug therapies? How do they expect the market to flex and adapt? Are the new arrivals likely to face an enthusiastic welcome or more of a tepid reception?

Covering 5 marketed drugs and 9 pipeline therapies, this report gives the viewpoint from 12 KOLs in North America and Europe. Find out what they think about prescribing trends for different patient segments, the various products coming through the pipeline, and the key issues influencing treatment choices.

Take a tour of the report now:

The table of contents >

The key questions answered >

The key KOL quotes >

See the 14 therapies covered >

Find out who the 12 EU & US KOLs are >

Review an extract from the report - 1 drug profile >

Sample of brands covered:

Uceris/Cortiment (budesonide MMX; Cosmo/Santarus/Ferring)

Entyvio (vedolizumab; Takeda)

Etrolizumab (RG 7413, rhuMab beta7; Roche)

Stelara (ustekinumab; Johnson & Johnson)

Plus 10 more – download the full list now >

Sample of KOLS interviewed

Dr. Adam Cheifetz, MD, Director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical School.

Prof Jean-Frédéric Colombel, MD, Professor of Medicine and Director of the Susan and Leonor Feinstein IBD Center at Icahn School of Medicine in New York, NY.

Prof Gerhard Rogler, MD, PhD, Professor of Gastroenterology and Hepatology and Ordinarius ad personam at the University of Zürich, based at the University hospital of Zurich.

Prof Laurent Peyrin-Biroulet, MD, PhD, Department of HepatoGastroenterology, University Hospital of Nancy, Vandoeuvre-les-Nancy, France.

Plus 8 more - download the full list now >

Top Takeaways

Possible change to mild-to-moderate UC treatment: What difference will LT 02 (controlled-release phosphatidylcholine) make to entrenched 5-ASA prescribing habits? Do KOLs see LT 02 as an alternative or an add-on for early stage patients?

One brand is still the preferred TNF inhibitor, but for how long? How do gastroenterologists feel about switching to biosimilars and are they 100% confident about efficacy? Should originators be concerned for their market share?

Patient education: Is patient perception that non-branded drugs are inferior a real problem or a perceived one? Do KOLs believe pharma is helping or hindering patient views on biosimilars? Could (and should) more be done to educate patients about treatment choices?

Views on a crowded moderate-to-severe drug pipeline: One trial has recently halted but with 8 more still actively progressing, which hold most promise for KOLs? Conversely, which head-to-head trial is viewed as ‘risky’ and which current study is described as ‘completely uninteresting’?

Two in-trial drugs are prompting more excitement than the rest: Which two potential new arrivals are viewed positively, but for different reasons? Could these be game changers for the severe patient segment?

Safety and cost dominate the debate: KOLs express cynicism about various pipeline drugs and possible treatment pathways, primarily due to side effect profiles and cost. The latter may also impact appetite for combination therapies, even though many KOLs are calling for this.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.>

You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.>

Table of Contents
for Ulcerative Colitis: KOL Insight

  • 1. Executive summary

    2. Research objectives

    3. Research focus

    4. Mild-to-moderate ulcerative colitis

    4.1 Overview 8

    4.2 Marketed drugs 9

    4.3 Uceris/Cortiment (budesonide MMX; Cosmo/Salix /Ferring) 9

    4.4 Pipeline drugs 14

    4.5 LT-02 (phosphatidylcholine controlled-release;

    4.6 Lipid Therapeutics/Dr Falk Pharma/Nestlé Health Science) 14

    5. Moderate-to-severe ulcerative colitis 20

    5.1 Overview 20

    5.2 Marketed drugs 21

    5.3 TNF inhibitors 21

    5.4 Entyvio (vedolizumab; Takeda) 39

    6. Pipeline drugs 51

    6.1 etrolizumab (RG7413, rhuMab beta7; Roche) 51

    6.2 carotegrast methyl (AJM300; EA Pharma/Kissei) 57

    6.3 Stelara (ustekinumab; Johnson & Johnson) 60

    6.4 Xeljanz (tofacitinib, CP-690,550; Pfizer) 67

    6.5 ozanimod (RPC 1063; Celgene) 74

    6.6 GS-5745 (Gilead Sciences) 79

    6.7 Kappaproct (cobitolimod, DIMS0150; InDex Pharmaceuticals) 83

    6.8 alicaforsen (ISIS 2302; Atlantic Healthcare/Ionis Pharmaceuticals)

    7. Current and future treatment algorithm 90

    8. Conclusion 93

    9. Appendix 95

    9.1 KOL biographies

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

65303 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Ulcerative Colitis - Pipeline Review, H1 2017
Ulcerative Colitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical an...
09 May 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Apr 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Feb 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
28 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Adalimumab Market Analysis: by Applications (Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis, and Others) and Geography – Forecast 2016-2021
Adalimumab, which is a patent product of the Abott Biotechnology Ltd., is a medication used for trea...
11 Mar 2016 by USD $5,250 (normally
USD $6,176)
More Info
SAVE 15% today! Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

Ulcerative Colitis: KOL Insight | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...